Evidence map›Paper›PMID 41285897›Full record

ArticleScientific reports2025

Identification of SARS-CoV-2 3CLpro inhibitors from marine actinomycetes through integrated phylogeny-based metabolomics with functional screening and bioinformatic analysis.

Doralyn S Dalisay, Jomari C Mateo, Jade Joshua R Teodosio, Lucille Marie S Jusa, Diane Monique S Baladjay, Leighiara S de Guzman, Lex Aliko P Balida, Jamia Azdina Jamal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. MarinePharmaceuticals (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Doralyn S DalisayCentre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia. ddalisay@usa.edu.ph.ORCID http://orcid.org/0000-0003-2850-7797
Jomari C MateoCenter for Chemical Biology and Biotechnology, University of San Agustin, 5000, Iloilo City, Philippines.
Jade Joshua R TeodosioCenter for Chemical Biology and Biotechnology, University of San Agustin, 5000, Iloilo City, Philippines.
Lucille Marie S JusaCenter for Chemical Biology and Biotechnology, University of San Agustin, 5000, Iloilo City, Philippines.
Diane Monique S BaladjayCenter for Chemical Biology and Biotechnology, University of San Agustin, 5000, Iloilo City, Philippines.
Leighiara S de GuzmanCenter for Chemical Biology and Biotechnology, University of San Agustin, 5000, Iloilo City, Philippines.
Lex Aliko P BalidaCenter for Chemical Biology and Biotechnology, University of San Agustin, 5000, Iloilo City, Philippines.
Jamia Azdina JamalCentre for Drug and Herbal Development, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the acute threat of the COVID-19 pandemic diminishes globally, advancing the research and development of antiviral agents remains crucial for ensuring preparedness for future outbreaks. This study investigates the inhibitory effects of marine sediment-derived actinomycetes on the SARS-CoV-2 main protease (3CLpro), a key enzyme involved in viral replication and transcription. Extracts of 75 actinomycete strains from two locations, Nogas Island in Antique and Tubbataha Reefs Natural Park in Palawan, Philippines, were evaluated for their ability to inhibit 3CLpro, with 36% of the extracts showing more than 90% inhibition. Further examination of 27 extracts revealed IC

Indexed as

ActinobacteriaAntiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsSARS-CoV-2Computational BiologyCOVID-19COVID-19 Drug TreatmentHumansMetabolomicsMolecular Docking SimulationPhylogeny3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsAntiviralsCarbazoleDiketopiperazinesFatty acid amideMarine actinomycetesMetabolomicsPhylogenetic analysisSARS-CoV-2 3CLpro inhibitorsSesquiterpenoid

Identifiers

PMID41285897
PMCPMC12644623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.